Aug 29 – Sept 2, 2020 Amsterdam, Holland
www.escardio.org
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-27 11:52:132023-09-06 08:06:22European society of cardiology
Proton therapy, a type of external beam radiation therapy, is a safe and effective treatment for prostate cancer, according to two new studies.
In the first study, researchers at the University of Florida in Jacksonville, Fla., prospectively studied 211 men with low-, intermediate-, and high-risk prostate cancer. The men were treated with proton therapy, a specialised type of external beam radiation therapy that uses protons instead of X-rays. After a two year follow-up, the research team led by Nancy Mendenhall, MD, of the University of Florida Proton Therapy Institute, reported that the treatment was effective and that the gastrointestinal and genitourinary side effects were generally minimal.
‘This study is important because it will help set normal tissue guidelines in future trials,’ Dr. Mendenhall, said.
In the second study, researchers from Massachusetts General Hospital in Boston, Loma Linda University Medical Center in Loma Linda, Calif., and the Radiation Therapy Oncology Group in Philadelphia performed a case-matched analysis comparing high-dose external beam radiation therapy using a combination of photons (X-rays) and protons with brachytherapy (radioactive seed implants).
Over three years, 196 patients received the external beam treatments. Their data was compared to 203 men of similar stages who received brachytherapy over the same time period. Researchers then compared the biochemical failure rates (a statistical measure of whether the cancer relapses) and determined that men who received the proton/photon therapy had the same rate of recurrence as the men who received brachytherapy.
‘For men with prostate cancer, brachytherapy and external beam radiation therapy using photons and protons are both highly effective treatments with similar relapse rates,’ John J. Coen, MD, a radiation oncologist at Massachusetts General Hospital in Boston, said. ‘Based on this data, it is our belief that men with prostate cancer can reasonably choose either treatment for localised prostate cancer based on their own concerns about quality of life without fearing they are compromising their chance for a cure.’
EurekAlert
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:43:112020-08-26 14:43:11Proton therapy effective prostate cancer treatment
Thanks to a new study from Columbia Engineering School, USA it may now be possible to diagnose non-periodic arrhythmias noninvasively and at low cost within a single heartbeat.
Non-periodic arrhythmias include atrial and ventricular fibrillation, which are associated with severely abnormal heart rhythm that can in some cases be life-threatening. Using Electromechanical Wave Imaging (EWI), the researchers sent unfocused ultrasound waves through the closed chest and into the heart. They were able to capture fast-frame-rate images that enabled them, for the first time, to map transient events such as the electromechanical activation that occurs over a few tens of milliseconds while also imaging the entire heart within a single beat. This means that physicians won
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:43:112023-09-06 08:32:01Diagnosing non-periodic arrhythmias at the point of care in a single heartbeat
Abiraterone has been approved since September 2011 for men with metastatic prostate cancer that is no longer responsive to hormone therapy and progresses further during or after therapy with the cytostatic drug docetaxel. In an early benefit assessment pursuant to the ‘Act on the Reform of the Market for Medicinal Products’ (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether abiraterone offers an added benefit compared with the present standard therapy.
IQWiG finds an indication of a considerable added benefit of abiraterone in patients who are not eligible for further treatment with docetaxel. In contrast, an added benefit is not proven in patients who can still be treated with docetaxel, as the dossier submitted by the drug manufacturer provides inadequate information for this group of patients.
In accordance with the specifications of the Federal Joint Committee (G-BA), IQWiG separately assessed abiraterone in two groups of patients. The G-BA has specified different appropriate comparator therapies for the two groups.
The ‘best supportive care population’ contains patients who are not eligible for further treatment with docetaxel. The appropriate comparator therapy for this group is palliative treatment with dexamethasone, prednisone, prednisolone or methylprednisolone, as well as ‘best supportive care’.
‘Best supportive care’ means the therapy that provides the patient with the best possible individually optimised supportive treatment to alleviate symptoms (e.g. adequate pain therapy) and improve quality of life.
The ‘docetaxel-retherapy population’ comprises patients who are still eligible for further treatment with docetaxel. The appropriate comparator therapy for this patient population is docetaxel in combination with prednisone or prednisolone.
Indication of increase in survival and delay in consequences of disease
One study (COU-AA-301), which considers patient-relevant outcomes and provides relevant data, was included in the assessment of added benefit in the ‘best supportive care population’. This study compared treatment with abiraterone versus placebo, in each case combined with prednisone and ‘best supportive care’.
IQWiG finds an indication of an added benefit in patients treated with abiraterone: the above study provides indications that abiraterone can prolong survival and delay consequences of prostate cancer, such as fractures or operations due to bone metastases. In addition, the ‘time to pain progression’ was prolonged in study participants receiving abiraterone.
IQWiG classifies the extent of this added benefit as ‘considerable’. The corresponding legal ordinance has specified three grades to determine the extent of added benefit: ‘minor’, ‘considerable’ and ‘major’.
The study data presented on health-related quality of life assessments cannot be used; an added benefit of abiraterone is therefore not proven for this outcome.
The indications of advantages for abiraterone are not accompanied by proof of greater harm.
Institute for Quality and Efficiency in Health Care
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:42:452020-08-26 14:43:09Abiraterone: Indication of considerable added benefit in certain patients
We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.
Google Analytics Cookies
These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
Other external services
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.
Privacy Beleid
U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.
CMEF
, /in Events /by 3wmediaAutumn 2020
TBC / TBC
ESICM LIVES 2020
, /in Events /by 3wmediaMadrid, Spain
www.esicm.org
Patient flow & bed management
, /in Events /by 3wmediaOct 5-8, 2020
www.equip-global.com
ISICEM
, /in Events /by 3wmediaSept 15-18, 2020
Brussels, Belgium
www.intensive.org
CIRSE 2020
, /in Events /by 3wmediaSept 12-16, 2020
Munich, Germany
www.cirse.org
HIMSS 2020
, /in Events /by 3wmediaSept 7-9, 2020
Helsinki, Finland
www.himssconference.org
European society of cardiology
Cardiology, /in Events /by 3wmediaAug 29 – Sept 2, 2020
Amsterdam, Holland
www.escardio.org
Proton therapy effective prostate cancer treatment
, /in E-News /by 3wmediaProton therapy, a type of external beam radiation therapy, is a safe and effective treatment for prostate cancer, according to two new studies.
In the first study, researchers at the University of Florida in Jacksonville, Fla., prospectively studied 211 men with low-, intermediate-, and high-risk prostate cancer. The men were treated with proton therapy, a specialised type of external beam radiation therapy that uses protons instead of X-rays. After a two year follow-up, the research team led by Nancy Mendenhall, MD, of the University of Florida Proton Therapy Institute, reported that the treatment was effective and that the gastrointestinal and genitourinary side effects were generally minimal.
‘This study is important because it will help set normal tissue guidelines in future trials,’ Dr. Mendenhall, said.
In the second study, researchers from Massachusetts General Hospital in Boston, Loma Linda University Medical Center in Loma Linda, Calif., and the Radiation Therapy Oncology Group in Philadelphia performed a case-matched analysis comparing high-dose external beam radiation therapy using a combination of photons (X-rays) and protons with brachytherapy (radioactive seed implants).
Over three years, 196 patients received the external beam treatments. Their data was compared to 203 men of similar stages who received brachytherapy over the same time period. Researchers then compared the biochemical failure rates (a statistical measure of whether the cancer relapses) and determined that men who received the proton/photon therapy had the same rate of recurrence as the men who received brachytherapy.
‘For men with prostate cancer, brachytherapy and external beam radiation therapy using photons and protons are both highly effective treatments with similar relapse rates,’ John J. Coen, MD, a radiation oncologist at Massachusetts General Hospital in Boston, said. ‘Based on this data, it is our belief that men with prostate cancer can reasonably choose either treatment for localised prostate cancer based on their own concerns about quality of life without fearing they are compromising their chance for a cure.’ EurekAlert
Diagnosing non-periodic arrhythmias at the point of care in a single heartbeat
Cardiology, /in E-News /by 3wmediaThanks to a new study from Columbia Engineering School, USA it may now be possible to diagnose non-periodic arrhythmias noninvasively and at low cost within a single heartbeat.
Non-periodic arrhythmias include atrial and ventricular fibrillation, which are associated with severely abnormal heart rhythm that can in some cases be life-threatening. Using Electromechanical Wave Imaging (EWI), the researchers sent unfocused ultrasound waves through the closed chest and into the heart. They were able to capture fast-frame-rate images that enabled them, for the first time, to map transient events such as the electromechanical activation that occurs over a few tens of milliseconds while also imaging the entire heart within a single beat. This means that physicians won
Abiraterone: Indication of considerable added benefit in certain patients
, /in E-News /by 3wmediaAbiraterone has been approved since September 2011 for men with metastatic prostate cancer that is no longer responsive to hormone therapy and progresses further during or after therapy with the cytostatic drug docetaxel. In an early benefit assessment pursuant to the ‘Act on the Reform of the Market for Medicinal Products’ (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether abiraterone offers an added benefit compared with the present standard therapy.
IQWiG finds an indication of a considerable added benefit of abiraterone in patients who are not eligible for further treatment with docetaxel. In contrast, an added benefit is not proven in patients who can still be treated with docetaxel, as the dossier submitted by the drug manufacturer provides inadequate information for this group of patients.
In accordance with the specifications of the Federal Joint Committee (G-BA), IQWiG separately assessed abiraterone in two groups of patients. The G-BA has specified different appropriate comparator therapies for the two groups.
The ‘best supportive care population’ contains patients who are not eligible for further treatment with docetaxel. The appropriate comparator therapy for this group is palliative treatment with dexamethasone, prednisone, prednisolone or methylprednisolone, as well as ‘best supportive care’.
‘Best supportive care’ means the therapy that provides the patient with the best possible individually optimised supportive treatment to alleviate symptoms (e.g. adequate pain therapy) and improve quality of life.
The ‘docetaxel-retherapy population’ comprises patients who are still eligible for further treatment with docetaxel. The appropriate comparator therapy for this patient population is docetaxel in combination with prednisone or prednisolone.
Indication of increase in survival and delay in consequences of disease
One study (COU-AA-301), which considers patient-relevant outcomes and provides relevant data, was included in the assessment of added benefit in the ‘best supportive care population’. This study compared treatment with abiraterone versus placebo, in each case combined with prednisone and ‘best supportive care’.
IQWiG finds an indication of an added benefit in patients treated with abiraterone: the above study provides indications that abiraterone can prolong survival and delay consequences of prostate cancer, such as fractures or operations due to bone metastases. In addition, the ‘time to pain progression’ was prolonged in study participants receiving abiraterone.
IQWiG classifies the extent of this added benefit as ‘considerable’. The corresponding legal ordinance has specified three grades to determine the extent of added benefit: ‘minor’, ‘considerable’ and ‘major’.
The study data presented on health-related quality of life assessments cannot be used; an added benefit of abiraterone is therefore not proven for this outcome.
The indications of advantages for abiraterone are not accompanied by proof of greater harm. Institute for Quality and Efficiency in Health Care